Cancer – AALL1231: Phase 3 Randomized Trial Investigating Bortexomib on a Modified Augmented BFM Backbone in Newly Diagnosed T-Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma
Condition or Therapy:
T-cell acute lymphoblastic leukemia and lymphoma
Cancer and Blood Disorders
Study Number: AALL1231
What is the goal of this study?
This study compares how patients with newly diagnosed T-cell acute lypmhoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma react when given or not given bortezomib while treated with chemotherapy.
Who can join the study?
This study may be a good fit for children and young adults who:
- are 2 to 30 years old, and
- are newly diagnosed with T-lymphoblastic leukemia (T-ALL) or T-lymphoblastic lymphoma (T-LLy) stages II-IV.
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or email the study coordinator.